Compare NUR & ADVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NUR | ADVB |
|---|---|---|
| Founded | N/A | 2014 |
| Country | Canada | Hong Kong |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8M | 8.6M |
| IPO Year | 2016 | 2023 |
| Metric | NUR | ADVB |
|---|---|---|
| Price | $0.40 | $2.44 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 446.6K | 68.4K |
| Earning Date | 08-28-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3431.25 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $127,637.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.60 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.36 | $1.80 |
| 52 Week High | $7.72 | $113.80 |
| Indicator | NUR | ADVB |
|---|---|---|
| Relative Strength Index (RSI) | 25.39 | 36.78 |
| Support Level | $0.36 | $1.80 |
| Resistance Level | $0.83 | $5.59 |
| Average True Range (ATR) | 0.09 | 0.53 |
| MACD | 0.00 | 0.17 |
| Stochastic Oscillator | 8.97 | 23.26 |
Nuran Wireless Inc is engaged in the Network as a Service (NAAS) business. The group operates in the research, development, manufacturing, marketing, and operation of digital electronic circuits and wireless telecommunication products and offers services in the mobile telephony industry. It also provides products and services that help mobile network operators profitably serve off-grid markets that are currently not served. It has two reportable segments: NaaS and Direct Sales. The majority of the revenue is derived from Africa.
Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.